November 12, 2026

New FDA Approved Indications for Bunnell LifePulse™ HFV

Bunnell announces a significant update to the approved LifePulse High Frequency 'Jet' Ventilator* Indications for Use which provides clinicians with more therapeutic flexibility to treat patients in acute respiratory failure.



The US FDA approves the LifePulse HFV to be indicated for treating pediatric patients (including neonates) who require temporary ventilatory support for acute respiratory failure. It is the responsibility of the clinician to determine the appropriate use of the LifePulse High Frequency Ventilator. The user needs to consider the respiratory status and the general state of health of the patient in order to optimally set ventilator settings for the patient's condition(s).

This update also includes the removal of the contraindication for the use of the LifePulse HFJV with an ETT smaller than 2.5mm.

For nearly 40 years, healthcare professionals have trusted Bunnell as a preferred partner in the treatment of critically ill infants. The LifePulse High Frequency Jet Ventilator sets the standard for effective, gentle ventilation.

For more information or questions, please visit our website at www.bunl.com, reach out to your designated Bunnell Clinical Specialist, or contact us at info@bunl.com.

**FDA record S056. The new approved indications currently applies to U.S. customers only.*

**Clinicians commonly refer to the LifePulse as the "Jet" ventilator or HFJV.*

330 Cutler Dr, North Salt Lake, UT, 84054 ● Voice: 800.800.4358 ● Fax: 801.467.0867 ● E-mail: info@bunl.com

Visit us online at www.bunl.com